A

Amgen

Makes biotech medicines for serious illnesses

Principal Scientist – AI/ML Workflow & Ecosystem Lead - Large Molecule Discovery Informatics

Full-Time
No salary listed
Senior
Bachelor's, Master's, PharmD, PhD, MD
Hyderabad, Telangana, India
In Person
AI & Machine LearningApplied Machine Learning

About the job

Requirements
  • A doctorate degree (PhD, PharmD, or MD) with relevant postdoctoral experience where applicable and 5 years of directly related experience, or a master's degree and 8 years of directly related experience, or a bachelor's degree and 10 years of directly related experience.
  • PhD with 5 or more years of experience applying artificial intelligence and machine learning in biotechnology, pharmaceutical, or related research and development environments.
  • Familiarity with large molecule or biologics discovery workflows.
  • Demonstrated experience translating computational models into production systems used in scientific or technical workflows.
  • Experience leading multidisciplinary teams across data, software, and scientific domains.
  • Strong understanding of machine learning lifecycle management, data engineering, and scalable system integration.
  • Experience with scientific data platforms, data modeling, and development of machine-learning-ready datasets.
  • Proven ability to lead complex, cross-functional initiatives in matrixed organizations.
  • Strong communication skills to influence and align stakeholders across scientific and technical domains.
  • Experience defining and measuring adoption and impact of digital or artificial-intelligence-driven capabilities.
Responsibilities
  • Lead the transition of artificial intelligence and machine learning models from research into production-ready solutions within Large Molecule Discovery, ensuring successful integration into domain-specific scientific workflows and informatics systems.
  • Lead and develop a multidisciplinary team responsible for AI enablement, data standards, and workflow integration within the Large Molecule Discovery ecosystem.
  • Drive adoption of AI/ML capabilities within Large Molecule Discovery by defining and implementing research-to-production handoff patterns for implementing machine-learning models in end-to-end discovery workflows, and enabling intuitive, reliable user experiences for scientists.
  • Provide clear priorities, coaching, and execution oversight to ensure delivery of high-quality, scalable capabilities across a diverse technical team.
  • Establish best practices for model reproducibility, documentation, governance, and compliance, aligned with enterprise standards and deployment frameworks.
  • Partner directly with experimental and computational scientists to identify high-impact opportunities for AI/ML integration and ensure solutions align with real-world scientific workflows.
  • Translate scientific research needs into clear technical, data, and workflow requirements, partnering with technology teams to deliver scalable, production-grade solutions.
  • Partner across scientific, data, and technology functions to ensure availability of high-quality, machine-learning-ready datasets and robust data pipelines supporting Large Molecule Discovery workflows.
  • Enable standardization of complex biological data, including sequencing and assay data, to support reproducible model training and downstream use in Large Molecule Discovery.
  • Define and advance ontology and metadata frameworks to ensure interoperability and long-term reuse of data across Large Molecule Discovery systems and modalities.
  • Monitor adoption, performance, and impact of deployed AI/ML capabilities within Large Molecule Discovery, including development of metrics, dashboards, and reporting.
  • Lead cross-functional initiatives within Large Molecule Discovery and coordinate across stakeholders to ensure alignment, manage scientific dependencies, and deliver integrated solutions at scale.
  • Collaborate with enterprise AI/ML strategy and platform teams to ensure alignment while representing Large Molecule Discovery-specific needs and priorities.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 31st, 2026
Amgen offers growth, income and stability, with revenue up 10% to $10.1B and a 2.3% yield

Amgen, the biotech giant, offers a mix of growth, income, and stability, according to a Motley Fool analysis. Second-quarter revenue rose 10% year over year to $10.1 billion, despite the coming loss of patent exclusivity for bone drug denosumab. Newer drugs such as Tezspire, Tepezza, and Imdelltra are driving sales. Imdelltra, combined with Imfinzi, cut the risk of death by 58% in a Phase 3 trial in certain small-cell lung cancer patients. Amgen's shares rose about 16% in 2022 as broader equities fell. It has raised its dividend every year since 2011, and the payout has grown 152% over the past decade. The forward yield is 2.3%, against 1.1% for the S&P 500.

Ars Technica
Oct 31st, 2026
FDA seeks to pull Tavneos over alleged data manipulation, but Amgen fights back

The US Food and Drug Administration (FDA) wants to withdraw approval of Tavneos, a drug for a rare autoimmune vasculitis, saying it was approved on manipulated trial data. In April, it sent Amgen a letter citing serious, sometimes fatal, liver injury and a lack of "substantial evidence" that the drug works. The FDA alleges ChemoCentryx, which Amgen bought for nearly $4 billion a year after approval, reassessed selected patients after unblinding the data and did not disclose it. Amgen says no clinical data were altered and the drug should stay available. Tavneos sales reached nearly half a billion dollars in fiscal year 2025. The EU has pulled the drug, the UK plans to, and a journal retracted the trial paper. A court hearing on a proposed $69 million investor settlement is expected on October 29.

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.